AUTL

Shares of Autolus Therapeutics (NASDAQ: AUTL) tanked by more than 20% in pre-market trading on Friday after the clinical-stage biopharmaceutical company announced the pricing of its public offering. Autolus will offer 75 million American Depositary Shares (ADS) in the United States representing 75 million ordinary shares at a price of $2.00 per ADS, for total gross proceeds of $150 million. Autolus scores a Strong Buy consensus rating from Wall Street analysts based on four unanimous Buys.
https://www.tipranks.com/news/autolus-tanks-after-pricing-of-public-offering?utm_source=advfn.com&utm_medium=referral